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Nonalcoholic steatohepatitis (NASH) is on track to become 
the leading contributor to the global burden of liver disease, 
in particular due to the finding that NASH is one of the com-
monest precursors of hepatocellular carcinoma (HCC) [1]. 
For example in the USA, while the percentage of total liver 
transplants for recipients with hepatitis C has decreased from 
35.3 to 23.6%, the percentage of liver transplants for NASH 
has increased [2]. Retrospective reviews of two large biopsy 
databases reported that up to 5% of HCV patients also had 
NASH [3] and up to one-third of individuals with chronic 
HCV have type 2 diabetes, which has been associated with 
worsening outcomes of HCV infection [4].
In this issue of Digestive Diseases and Sciences, Ben-
hammou and colleagues evaluated the effects of NAFLD 
risk factors including obesity and diabetes on the long-term 
outcomes of patients with HCV treated with direct-acting 
antivirals (DAAs) [5]. The authors conducted a retrospec-
tive study off 33,003 DAA treated US Veterans between 
2013 and 2015. The patients were categorized using the 
body mass index (BMI); diabetes was identified using ICD 
9/10 codes in association with hemoglobin A1c > 6.5% 
or having an active prescription for diabetes medications. 
Patients were evaluated for the development of cirrhosis, 
liver decompensation, or the development of HCC and death 
with a mean follow-up of 3 years. They found an association 
between the presence of diabetes and increased mortality 
and liver-related adverse outcomes including HCC, even 
among patients without baseline cirrhosis. Patients who 
were obese also exhibited a higher risk of developing cir-
rhosis compared with normal-weight patients although sur-
prisingly they had a lower risk of mortality and of develop-
ing HCC.
These results underscore the importance of diabetes as 
an independent risk factor for liver disease, and in particu-
lar, HCC development. In contrast to prior experiences with 
IFN-based treatments, the presence of insulin resistance or 
type 2 diabetes mellitus did not appear to diminish the rate 
of sustained virological response (SVR) to DAA treatments 
[6]. Conversely, while several early studies had suggested 
that DAA-associated SVR improves the metabolic status, 
two of those studies did not observe long-term glycemic 
control [7]. Though the current study did not examine if 
DAA treatment changed insulin resistance, these data are 
unlikely to be available in an administrative retrospective 
study, especially since insulin resistance is not measured in 
routine clinical practice. Future prospective studies should 
evaluate this potential association between DAA-associated 
SVR, changes in insulin resistance, and liver outcomes.
It is particularly worrisome that a significant number of 
patients with pre-existing diabetes developed HCC within 
a 3-year follow-up period (hazard ratio of 1.4). Generally, 
HCC develops on a background of cirrhosis or advanced 
fibrosis; in particular, the risk of HCC development among 
those who achieve HCV SVR and who do not have cirrhosis 
or advanced fibrosis is low [8]. This report suggests other-
wise; that this is not necessarily the case for individuals with 
concomitant diabetes, and is consistent with a prior meta-
analysis of 25 studies which showed that those with type 2 
diabetes mellitus have an increased risk of HCC, even in 
the absence of pre-existing cirrhosis [9]. Since NAFLD is 
common among those with T2DM [9], one could speculate 
that the majority of those with pre-existing diabetes have 
concomitant NAFLD. Nevertheless, without the availability 
of histological data, it is unclear if those who subsequently 
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developed HCC had concomitant NASH, and if they had 
early or advanced liver fibrosis. These data are clinically 
relevant since they beg the question of whether individuals 
who achieved HCV SVR without liver cirrhosis should con-
tinue to be monitored or undergo HCC surveillance. Future 
multicenter studies will be needed in order to address this 
question, and perhaps identify those with diabetes most 
likely to develop HCC.
This study reinforces the limitations of using BMI to 
stratify metabolic and liver disease risks, and is consist-
ent with the current WHO definition of the metabolic syn-
drome where obesity is defined by the presence of truncal 
obesity [10]. Patients with a high BMI may include those 
without sarcopenia; furthermore, the presence of ascites 
also increases body weight. Therefore, individuals with 
sarcopenia could have a normal BMI. Although the waist 
and hip circumference measurements are currently not rou-
tinely recorded in most routine practice settings, it would be 
important to evaluate if they are associated with HCC devel-
opment and/or overall mortality. Perhaps the most promising 
method of simultaneously, objectively, and noninvasively 
assessing sarcopenia, visceral obesity, and liver morphology 
is the non-contrast abdominal CT scan, that has become an 
effective tool in this regard [11].
Despite the short follow-up, this study adds to the current 
literature, highlighting the contribution of metabolic risk 
factors such as T2DM as key drivers of chronic liver disease, 
including NAFLD and HCC. Given the rising NAFLD bur-
den in the USA, providers should be cognizant of concomi-
tant NAFLD risk factors and the potential risk of ongoing 
NAFLD-associated liver disease progression in those who 
achieve HCV SVR.
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